NIH Director’s New Innovator Award (DP2 Clinical Trial Optional)
NIH Common Fund (NIH-CF) · NIH Institute/Center · RFA-RM-27-002
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $475K
- DeadlineFinal application due date.
- Aug 17, 2026
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- DP2
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 30
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- One-time
- Open dateWhen applications open (or opened).
- Jun 26, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $23M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Optional / allowed
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
The NIH Director"s New Innovator Award supports early-stage investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. Applications in any area within the biomedical sciences are welcome; topics may involve basic, translational, or clinical research. The NIH Director's New Innovator Award complements other ongoing efforts by NIH and its Institutes and Centers to fund early-stage investigators. The NIH Director"s New Innovator Award is a component of the High-Risk, High-Reward Research (HRHR) program of the NIH Common Fund.